Rain Oncology Inc
(NAS:RAIN)
$
1.21
0 (0%)
Market Cap: 44.02 Mil
Enterprise Value: -32.85 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 22/100 Rain Oncology Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 21, 2023 - Feb 23, 2023 / 05:00PM GMT
Release Date Price:
$8.67
(-8.79%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director
Okay, great. Welcome, everyone, to the first day of the Virtual Oncology Summit, hosted by Citigroup. I'm Yigal Nochomovitz, one of the biotech analysts. The next session is with Rain Oncology, and it's my pleasure to have with me the Co-Founder, Chairman and CEO, Avanish Vellanki. Welcome, Avanish. Thanks so much for taking the time.
Avanish Vellanki
Rain Oncology Inc. - Co-Founder, CEO & Chairman
Thanks for having us, Yigal.
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director
So I think a lot of people are pretty familiar with the story. So maybe it would be helpful if you could just do, though, a quick 2- to 3-minute elevator pitch on the company, and then we can jump into the key questions on your upcoming big Phase III readout.
Avanish Vellanki
Rain Oncology Inc. - Co-Founder, CEO & Chairman
Absolutely. Happy to. So Rain Oncology is a precision oncology
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot